Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01880957 · ClinicalTrials.gov registry record · NA
PET and MRI Brain Imaging of Bipolar Disorder
A NA study, sponsored by Stony Brook University.
- Completed
- Registry status
- NA
- Development phase
- 76
- Enrollment target
NCT01880957 is a NA study that has completed, run by Stony Brook University. The registered enrollment target is 76 participants.
The verdict
NCT01880957, a NA study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
Study Summary
The primary aims of this study are to: 1. Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE). 2. Assess the effect of lithium treatment of bipolar disorder on 5-HTT. 3. Assess the effect of lithium treatment of bipolar disorder on 5-HT1A BP. 4. Assess the effect of lamotrigine treatment of bipolar disorder on 5-HTT and 5-HT1A BP. 5. Assess the effect of lithium treatment of unipolar depression on 5-HTT BP.
Interventions
- DRUG Lamotrigine
- DRUG Lithium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2011-11-08 |
| Est. Completion | 2017-06-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01880957
The ClinicalTrials.gov registry entry for NCT01880957 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lamotrigine is the first listed.
NCT01880957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01880957 about?
NCT01880957 is a clinical study titled "PET and MRI Brain Imaging of Bipolar Disorder". The primary aims of this study are to: 1. Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE). 2. Assess the effect of lithium treatment of bipolar disorder on 5-HTT. 3. Assess the effect of lithium treatme...
What is the current status of trial NCT01880957?
This trial is currently completed. It is a NA study. The enrollment target is 76 participants. The study started on 2011-11-08. Estimated completion is 2017-06-23.
What interventions are being tested in trial NCT01880957?
The interventions under investigation include: Lamotrigine (DRUG), Lithium (DRUG).
Who is sponsoring clinical trial NCT01880957?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.